Andrew Cheng

11.1k total citations · 6 hit papers
95 papers, 7.5k citations indexed

About

Andrew Cheng is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Andrew Cheng has authored 95 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Infectious Diseases, 59 papers in Virology and 28 papers in Emergency Medicine. Recurrent topics in Andrew Cheng's work include HIV/AIDS drug development and treatment (76 papers), HIV Research and Treatment (59 papers) and HIV/AIDS Research and Interventions (42 papers). Andrew Cheng is often cited by papers focused on HIV/AIDS drug development and treatment (76 papers), HIV Research and Treatment (59 papers) and HIV/AIDS Research and Interventions (42 papers). Andrew Cheng collaborates with scholars based in United States, United Kingdom and France. Andrew Cheng's co-authors include Edwin DeJesus, Joel E. Gallant, Anton Pozniak, Lijie Zhong, Jeffrey Enejosa, Brian P. Kearney, Damian J. McColl, Kirsten White, Michael D. Miller and José Ramón Arribas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Andrew Cheng

94 papers receiving 7.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. profile →
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Joel E. Gallant, Anthony Mills et al. The Lancet profile →
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

2021 255 citations Stephen A. Harrison, Peter Ruane et al. profile →
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

2023 146 citations Stephen A. Harrison, Juan P. Frías et al. profile →
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

2025 19 citations Guy Neff, Doreen Chan et al. profile →

Peers

Countries citing papers authored by Andrew Cheng

Since Specialization

Citations

This map shows the geographic impact of Andrew Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Cheng more than expected).

Fields of papers citing papers by Andrew Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Cheng. The network helps show where Andrew Cheng may publish in the future.

Co-authorship network of co-authors of Andrew Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Cheng. A scholar is included among the top collaborators of Andrew Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Cheng. Andrew Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes 2024 ·Diabetes ·Kathryn Jean Lucas, (unknown), Doreen Chan, Erik J. Tillman, (unknown), Brittany de Temple, (unknown), (unknown), Tim Rolph, Andrew Cheng, Kitty Yale	1
2	Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study 2024 ·Clinical Gastroenterology and Hepatology ·Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, (unknown), Doreen Chan, Erik J. Tillman, (unknown), Brittany de Temple, (unknown), Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale	37
3	Comparative evaluation of a laboratory-developed real-time PCR assay and RealStar® Adenovirus PCR Kit for quantitative detection of human adenovirus 2018 ·Virology Journal ·Samson S. Y. Wong, Cyril Chik‐Yan Yip, Siddharth Sridhar, Kit‐Hang Leung, Andrew Cheng, Ami M. Y. Fung, Hoyin Lam, Kwok‐Hung Chan, Jasper Fuk‐Woo Chan, Vincent Chi‐Chung Cheng, Bone S. F. Tang, Kwok‐Yung Yuen	12
4	P075 Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women 2017 ·Sexually Transmitted Infections ·Sally Hodder, Kathleen Squires, Cissy Kityo, Anchalee Avihingsanon, (unknown), Shuping Jiang, Rima Kulkarni, Andrew Cheng, (unknown), Huyen Cao	1
5	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study 2017 ·The Lancet HIV ·Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia Martorell, (unknown), Hans‐Jürgen Stellbrink, Jean‐Michel Molina, Frank A. Post, Ignacio Valero, Danielle Porter, Ya-Pei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao	37
6	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial breakdown → 2017 ·The Lancet ·Paul E. Sax, Anton Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph M. Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk	278
7	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
8	Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study 2016 ·The Lancet HIV ·Kathleen Squires, Cissy Kityo, Sally Hodder, Margaret Johnson, Evgeny Voronin, Debbie Hagins, Anchalee Avihingsanon, Ellen Koenig, Shuping Jiang, Kirsten White, Andrew Cheng, Javier Szwarcberg, Huyen Cao	62
9	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, (unknown), Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	158
10	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister	121
11	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Frank A. Post, Jonathan Winston, Jaime Andrade‐Villanueva, Martin Fisher, Ya-Pei Liu, Christophe Béraud, Michael E. Abram, Hiba Graham, Martin S. Rhee, Andrew Cheng, Javier Szwarcberg	11
12	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results 2013 ·The Journal of Infectious Diseases ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew Cheng	84
13	Week 96 renal safety update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from two phase 3 randomized controlled trials 2013 ·Journal of the International AIDS Society ·Frank Post, Jonathan Winston, (unknown), Brian Gazzard, Jean‐Michel Molina, (unknown), David Piontkowsky, Andrew Cheng, Martin S. Rhee, Javier Szwarcberg	1
14	Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·S. Ramanathan, Anita Mathias, Xuelian Wei, Gong Shen, Joanna Koziara, Andrew Cheng, Brian P. Kearney	34
15	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	335
16	Absence of Clinically Relevant Pharmacokinetic Interaction Between Ribavirin and Tenofovir in Healthy Subjects 2006 ·The Journal of Clinical Pharmacology ·S. Ramanathan, Andrew Cheng, (unknown), Ramin Ebrahimi, Brian P. Kearney	11
17	Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine 2005 ·The Journal of Clinical Pharmacology ·Brian P. Kearney, (unknown), John F. Flaherty, Shanshan Chen, Sanjeev Kaul, Andrew Cheng	39
18	Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Damian J. McColl, Nicolas Margot, Michael Wulfsohn, Dion F. Coakley, Andrew Cheng, Michael D. Miller	40
19	Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF 2002 ·AIDS ·Nicolas Margot, (unknown), Ian McGowan, Andrew Cheng, Robert T. Schooley, Michael D. Miller	126
20	The murine LIM-kinase gene (limk) encodes a novel serine threonine kinase expressed predominantly in trophoblast giant cells and the developing nervous system 1995 ·Mechanisms of Development ·Andrew Cheng, Elizabeth Robertson	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact